SCHEMBL880412

SCHEMBL880412

Cc1cc(NC(=O)c2ccc(F)cc2)n(-c2nc3ccccc3[nH]2)n1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.84
KDM4E B2RXH2 4/20 0.84
NPSR1 Q6W5P4 7/20 0.77
SMN1; SMN2 Q16637 5/20 0.77
L3MBTL1 Q9Y468 2/20 0.77
GAA P10253 2/20 0.77
MAPT P10636 11/20 0.74
KMT2A Q03164 8/20 0.74
MEN1 O00255 7/20 0.74
HTT P42858 6/20 0.74
TDP1 Q9NUW8 6/20 0.74
POLB P06746 2/20 0.74
HPGD P15428 2/20 0.74
CYP1A2 P05177 2/20 0.74
CYP3A4 P08684 2/20 0.74
CYP2C9 P11712 2/20 0.74
CYP2C19 P33261 2/20 0.74
CYP2D6 P10635 1/20 0.74
NPC1 O15118 1/20 0.71
LMNA P02545 5/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13522300 0.92 ALDH1A1 (0.88) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL880478 0.90 ALDH1A1 (0.84) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL880481 0.88 KDM4E (0.81) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL880413 0.83 ALDH1A1 (0.77) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL880480 0.80 MAPT (1.00) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL10280642 0.79 ALDH1A1 (0.70) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL880258 0.79 NPSR1 (0.92) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL29004406 0.78 KDM4E (0.69) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL23160937 0.78 ADCY1 (0.72) KMT2AMEN1LMNAADCY8ADCY1
SCHEMBL23188322 0.78 ADCY1 (1.00) ADCY8ADCY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 EP disclosed
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-01-07 US disclosed
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-01-07 US disclosed
WO-2007089548-A2 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING GOLT1B, NPC1L1, NPC1 ALDH1A1 3699/4885KDM4E 4172/4885NPSR1 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.